The Public Cannabis Company Revenue Tracker, managed by New Cannabis Ventures, ranks the top revenue producing cannabis stocks that generate industry sales of more than US$2.5 million per quarter. This data-driven, fact-based tracker will continually update based on new financial filings so that readers can stay up to date. Companies must file with the SEC or SEDAR to be considered for inclusion.
43 companies currently qualify for inclusion, with 27 filing in U.S dollars and 16 in the Canadian currency. Since our last report in mid-February, we have added GW Pharma(NASDAQ: GWPH) and Green Growth Brands (CSE:GGB) (OTC: GGBXF). We expect to add several companies in the coming months, including TILT Holdings (CSE: TILT) (OTC: SVVTF), which announced very strong January pro forma revenue and is likely to qualify for its Q4, which should be reported in March or April.
In late February, GW Pharma returned to the list of leading revenue generators in the transitional quarter ending 12/31. The company had previously used a fiscal year-end of September, but, for 2019, the year-end will be December, leaving the last quarter as a stand-alone and not part of any full year. During the quarter, the company began to report sales from Epidiolex, which represented 71% of overall sales, with the balance in Sativex, which declined from a year ago. Overall sales were slightly ahead of expectations. MedMen Enterprises (CSE: MMEN) (OTC: MMNFF) reported its FY19-Q2 financials on February 27th and took, for now, the top spot, with sales of $29.9 million in its Q2, representing 39% growth from the prior quarter. Green Growth Brands reported revenue related to its Nevada operations, its first quarter of sales since its reverse-merger.
A great number of companies are scheduled to report in March, including Acreage Holdings(CSE: ACRG.U) (OTC: ACRGF), which will host a call on March 13th, Cannex Capital (CSE: CNNX) (OTC: CNXXF), CV Sciences (OTC: CVSI), which will host a call on March 12th, GrowGeneration (OTC: GRWG), Helix TCS (OTC: HLIX), Innovative Industrial Properties(NYSE: IIPR), which will host a call on March 14th, Marimed (OTC: MRMD), Medicine Man Technologies (OTC: MDCL), Surna (OTC: SRNA), Terra Tech (OTC: TRTC) and Tilray (NASDAQ: TLRY), which will host a call on March 18th. According to Sentieo, IIPR is expected to have generated $4.76 million in revenue in its Q4, w hich would represent 109% growth from a year ago. The company’s EPS are expected to be $0.26, up from $0.20 in Q3 and from $0.03 a year ago. Tilray is expected to generate sales of $14 million, up from $10 million in Q3.
Of the companies that report in Canadian dollars, Isodiol International (CSE: ISOL) (OTC: ISOLF) was the only one to report in the second half of February. The company’s business has slowed dramatically in recent quarters.
In March, we expect reports from 1933 Industries (CSE: TGIF) (OTC: TGIFF), Alcanna (TSX: CLIQ) (OTC: LQSIF), which hosts a call on March 15th, CannTrust (TSX: TRST) (NYSE: CTST), Cronos Group (TSX: CRON) (NASDAQ: CRON), which will host a call on March 26th, HEXO Corp (TSX: HEXO) (NYSE American: HEXO), Namaste Technologies (TSXV: N) (OTC: NXTTF) and Nutritional High (CSE: EAT) (OTC: SPLIF). According to Sentieo, analysts project CannTrust will generate sales of C$21.2 million, up 68% from Q3 and 203% from a year ago. Cronos Group is expected to generate sales of C$11.4 million, up 221% from the prior quarter and 609% from a year ago. HEXO is expected to have generated sales of C$14.6 million in its fiscal Q2, up 157% from the prior quarter and up 1135% from a year ago.
Visit the Public Cannabis Company Revenue Tracker to track and explore the complete list of qualifying companies. For our readers who are interested in staying on top of scheduled earnings calls in the sector, we have recently introduced the Cannabis Investor Earnings Conference Call Calendar.